Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,096 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Wearable based monitoring and self-supervised contrastive learning detect clinical complications during treatment of Hematologic malignancies.
Jacobsen M, Gholamipoor R, Dembek TA, Rottmann P, Verket M, Brandts J, Jäger P, Baermann BN, Kondakci M, Heinemann L, Gerke AL, Marx N, Müller-Wieland D, Möllenhoff K, Seyfarth M, Kollmann M, Kobbe G. Jacobsen M, et al. Among authors: jager p. NPJ Digit Med. 2023 Jun 2;6(1):105. doi: 10.1038/s41746-023-00847-2. NPJ Digit Med. 2023. PMID: 37268734 Free PMC article.
Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation.
Rautenberg C, Bergmann A, Germing U, Fischermanns C, Pechtel S, Kaivers J, Jäger P, Schuler E, Haas R, Kobbe G, Schroeder T. Rautenberg C, et al. Among authors: jager p. Cancers (Basel). 2020 Aug 12;12(8):2255. doi: 10.3390/cancers12082255. Cancers (Basel). 2020. PMID: 32806572 Free PMC article.
Feasibility of Wearable-Based Remote Monitoring in Patients During Intensive Treatment for Aggressive Hematologic Malignancies.
Jacobsen M, Rottmann P, Dembek TA, Gerke AL, Gholamipoor R, Blum C, Hartmann NU, Verket M, Kaivers J, Jäger P, Baermann BN, Heinemann L, Marx N, Müller-Wieland D, Kollmann M, Seyfarth M, Kobbe G. Jacobsen M, et al. Among authors: jager p. JCO Clin Cancer Inform. 2022 Jan;6:e2100126. doi: 10.1200/CCI.21.00126. JCO Clin Cancer Inform. 2022. PMID: 35025669
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Schroeder T, Stelljes M, Christopeit M, Esseling E, Scheid C, Mikesch JH, Rautenberg C, Jäger P, Cadeddu RP, Drusenheimer N, Holtick U, Klein S, Trenschel R, Haas R, Germing U, Kröger N, Kobbe G. Schroeder T, et al. Among authors: jager p. Haematologica. 2023 Nov 1;108(11):3001-3010. doi: 10.3324/haematol.2022.282570. Haematologica. 2023. PMID: 37259567 Free PMC article.
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies.
Schulz F, Jäger P, Tischer J, Fraccaroli A, Bug G, Hausmann A, Baermann BN, Tressin P, Hoelscher A, Kasprzak A, Nachtkamp K, Schetelig J, Hilgendorf I, Germing U, Dietrich S, Kobbe G. Schulz F, et al. Among authors: jager p. Cancers (Basel). 2024 Jan 26;16(3):532. doi: 10.3390/cancers16030532. Cancers (Basel). 2024. PMID: 38339283 Free PMC article.
Aggressive Lymphoma after CD19 CAR T-Cell Therapy.
Kobbe G, Brüggemann M, Baermann BN, Wiegand L, Trautmann H, Yousefian S, Libertini S, Menssen HD, Maier HJ, Ulrich P, Gao J, Bruch PM, Liebers N, Radujkovic A, Seifert M, Schniederjohann C, Paramasivam N, Fitzgerald D, Seidel M, Esposito I, Germing U, Cadeddu RP, Nachtkamp K, Jäger P, Ulrych T, Fischer JC, Rox JM, Giesel F, Koch R, Antoch G, Distler JHW, Meuth SG, Jacobsen M, Hübschmann D, Lu J, Iaccarino I, Haas S, Damm F, Dietrich S. Kobbe G, et al. Among authors: jager p. N Engl J Med. 2024 Oct 3;391(13):1217-1226. doi: 10.1056/NEJMoa2402730. N Engl J Med. 2024. PMID: 39589371
1,096 results